Maximus, Inc. (NYSE:MMS) Director Jan Madsen Sells 2,439 Shares

Maximus, Inc. (NYSE:MMS) Director Jan Madsen sold 2,439 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $67.71, for a total transaction of $165,144.69. Following the sale, the director now directly owns 18,097 shares of the company’s stock, valued at $1,225,347.87. The trade was a 11.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Maximus Trading Up 0.3 %

MMS traded up $0.19 on Wednesday, hitting $68.74. The company had a trading volume of 432,431 shares, compared to its average volume of 481,637. Maximus, Inc. has a 1 year low of $63.77 and a 1 year high of $93.97. The firm has a market cap of $3.89 billion, a P/E ratio of 14.78 and a beta of 0.71. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.82. The company’s fifty day moving average price is $71.48 and its 200 day moving average price is $78.89.

Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, February 6th. The health services provider reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. As a group, equities analysts expect that Maximus, Inc. will post 6.15 earnings per share for the current year.

Maximus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Saturday, February 15th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $1.20 dividend on an annualized basis and a yield of 1.75%. Maximus’s dividend payout ratio (DPR) is presently 25.81%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Raymond James upgraded shares of Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 price target for the company in a research note on Thursday, January 2nd. StockNews.com cut shares of Maximus from a “buy” rating to a “hold” rating in a report on Friday, February 14th.

Institutional Trading of Maximus

Several hedge funds have recently added to or reduced their stakes in MMS. Norges Bank acquired a new position in Maximus during the fourth quarter valued at $71,443,000. SG Capital Management LLC bought a new position in Maximus in the 4th quarter valued at $30,285,000. Federated Hermes Inc. lifted its holdings in Maximus by 74.8% during the fourth quarter. Federated Hermes Inc. now owns 882,953 shares of the health services provider’s stock worth $65,912,000 after acquiring an additional 377,705 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Maximus in the 4th quarter valued at about $22,661,000. Finally, Voloridge Investment Management LLC increased its position in shares of Maximus by 306.8% in the fourth quarter. Voloridge Investment Management LLC now owns 376,055 shares of the health services provider’s stock valued at $28,073,000 after acquiring an additional 283,608 shares during the last quarter. Institutional investors own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.